Music lessons may sharpen minds in schizophrenia
NCT ID NCT07055204
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether learning music—rhythm, singing, and body movements—can improve attention and thinking in people with schizophrenia. About 120 adults with stable schizophrenia will take part. The goal is to see if music-based training is a more engaging and effective way to boost cognitive skills than standard programs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with a diagnosis of schizophrenia or schizoaffective disorder (DSM-5 TR criteria) * Clinically stable (no full-time hospitalization related to schizophrenia for 3 months) * Regular psychiatric follow-up * Enrolled in at least 1 therapeutic or social out-of-home activity * No change in the antipsychotic treatment for 3 months (medication and/or dosage) * Have given free, informed and written consent to participate in the study. * Patient affiliated or beneficiary of a social security scheme Exclusion Criteria: * Patient with moderate to severe intellectual disability (clinical criteria) * Engaged in a Social rythmic or musical activity * Presenting an addictive comorbidity (excluding tobacco addiction and behavioural addictions) * Presenting a neurological pathology with cognitive impact * Involved in a neurocognitive remediation program
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assistance Publique Hôpitaux de Marseille
NOT_YET_RECRUITINGMarseille, France
-
Association route nouvelle
RECRUITINGToulouse, France
-
CH Gérard Marchant
RECRUITINGToulouse, France
-
CH Le Vinatier
RECRUITINGBron, France
-
CH de la Côte Basque
RECRUITINGBayonne, France
-
Centre de Santé MGEN
RECRUITINGToulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug